LEAP THERAPEUTICS, INC. (LPTX) - Dilution Analysis

10-Q filing | 106.5M shares outstanding

10-K filing | 90.0M shares outstanding

8-K filing: Cypherpunk Technologies Inc. granted 5,448,157 restricted stock units (RSUs) to CoinXit Ltd. under the Company's 2025 Equity Incentive Plan, which also terminated and cancelled a previous RSU grant of 2,411,700 RSUs issued pursuant to the November 2025 CoinXit RSUs Agreement.

8-K filing: Cypherpunk Technologies Inc. grants restricted stock units (RSUs) to CoinXit Ltd., its directors, and employees, contingent upon certain conditions, and enters into consulting and employment agreements.

8-K filing: Leap Therapeutics, Inc. entered into a Securities Purchase Agreement for a private placement involving the issuance of common stock, pre-funded warrants, and common warrants, which closed on October 8, 2025, resulting in gross proceeds of approximately $58.88 million. ($49.89M proceeds)

10-Q filing | 41.3M shares outstanding

10-K filing | 25.6M shares outstanding

10-Q filing | 25.6M shares outstanding

10-Q filing | 25.6M shares outstanding

10-Q filing | 27.0M shares outstanding

S-3 filing: This S-3 filing relates to the possible resale of up to 14,184,397 shares of common stock by selling stockholders.

8-K filing: Leap Therapeutics, Inc. entered into a Securities Purchase Agreement to sell shares of common stock and pre-funded warrants to certain institutional investors for gross proceeds of approximately $40 million. ($40.0M proceeds)

10-K filing | 25.6M shares outstanding

S-3 filing: Leap Therapeutics, Inc. files an S-3 registration statement to offer and sell shares of common stock, preferred stock, warrants, debt securities, and rights to purchase these securities, or units in any combination, with an aggregate offering price of up to $200,000,000.

10-Q filing | 27.0M shares outstanding

10-Q filing | 25.6M shares outstanding

S-3/A filing: This prospectus relates to the possible resale or other disposition from time to time by the selling stockholders named in this prospectus of up to an aggregate of 162,677,093 shares of common stock of Leap Therapeutics, Inc.

10-Q filing | 129.3M shares outstanding

S-3 filing: This is an S-3 filing for the resale of up to 147,073,093 shares of common stock by selling stockholders, including shares issued in connection with the acquisition of Flame Bioscience, Inc.

10-K filing | 59.7M shares outstanding

8-K filing: Leap Therapeutics acquired Flame Biosciences, issuing approximately 19,794,373 shares of common stock and 136,833 shares of Series X Non-Voting Convertible Preferred Stock, with each share of Series X Preferred Stock convertible into 1,000 shares of Common Stock, subject to stockholder approval.

10-Q filing | 99.0M shares outstanding

10-Q filing | 88.3M shares outstanding

10-Q filing | 88.3M shares outstanding

10-K filing | 59.7M shares outstanding

10-Q filing | 87.8M shares outstanding

10-Q filing | 59.7M shares outstanding

10-Q filing | 59.7M shares outstanding

10-K filing | 59.7M shares outstanding

10-Q filing | 59.7M shares outstanding

S-3/A filing: This is an S-3/A filing including the form of pre-funded warrant to purchase common stock.

S-3 filing: Leap Therapeutics, Inc. intends to offer and sell shares of common stock, shares of preferred stock, warrants, debt securities and rights to purchase common stock, preferred stock, debt securities or units, as well as units that include any of these securities, with an aggregate offering price of up to $150,000,000.

10-Q filing | 59.7M shares outstanding

8-K filing: Leap Therapeutics, Inc. entered into an underwriting agreement for a public offering of 20,250,000 shares of common stock at $2.00 per share and pre-funded warrants to purchase 2,250,000 shares at $1.999 per warrant, with an underwriter option for an additional 3,375,000 shares at $2.00 per share. ($45.0M proceeds)

10-K filing | 35.8M shares outstanding

8-K filing: Leap Therapeutics, Inc. entered into a Securities Purchase Agreement for a private placement, issuing Series A and Series B Preferred Stock, and Special Voting Stock for approximately $27 million in gross proceeds, subject to stockholder approval for conversion into common stock and warrants. ($54.0M proceeds)